Di Somma C, Canepa G, Gipponi M, Frascio M
Cattedra di semeiotica chirurgica R, Università di Genova.
Ann Ital Chir. 1992 Jan-Feb;63(1):83-8.
Postoperative thromboembolic complications do present an underestimated problem whenever their detection simply relies upon individual clinical judgement. Major abdominal operations are at increased risk of pulmonary embolism (PE) and deep vein thrombosis (DVT), mostly in advanced age, overweight subject, and in patients with cardiac or malignant diseases, or with previous venous diseases. Such patients may benefit from a peri- and postoperative prophylaxis with chemical or mechanical procedures, as a recent meta-analysis seems to suggest. In our experience, a randomized, multicentric clinical trial with defibrotide (DF) versus calcium-heparin (CH) was realized with the aim of evaluating their effectiveness and side effects in the prophylaxis of PE and DVT after major abdominal surgery; 1296 patients were randomly assigned to i.v. DF (400 mg.) or subcutaneous CH (0.2 ml. = 5000 U.I.) given one hour prior to operation and twice daily for seven days postoperatively. Definitive evaluation was carried out on 1212 patients (610 patients in DF and 602 in CH group, respectively) who completed the prophylaxis and monitoring schedule acceptably. One PE (0.16%) and 38 DVT (6.2%) were detected in DF group while 2 PE (0.33%) and 40 DVT (6.6%) were reported in CH treated patients. Post-operative blood loss was 578 +/- 150 cc. (median +/- S.E.M.) in DF group and 604 +/- 123 in CH group (p = n.s.). Wound hematoma was observed in 69 patients (5.7%): 20 (3.2%) in DF and 49 (8.1%) in CH group of patients (CHI-Square = 12.44; p = 0.0005); a significant post-operative decrease of RBC, WBC, Platelet count, and Fibrinogen was computed in both groups (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
只要术后血栓栓塞并发症的检测仅依赖于个体临床判断,那么这确实是一个被低估的问题。大型腹部手术发生肺栓塞(PE)和深静脉血栓形成(DVT)的风险增加,主要见于高龄、超重患者,以及患有心脏疾病或恶性疾病、或既往有静脉疾病的患者。正如最近一项荟萃分析所表明的,这类患者可能从围手术期和术后采用化学或机械方法进行预防中获益。根据我们的经验,开展了一项比较去纤苷(DF)与钙肝素(CH)的随机、多中心临床试验,目的是评估它们在预防大型腹部手术后PE和DVT方面的有效性和副作用;1296例患者被随机分配接受静脉注射DF(400毫克)或皮下注射CH(0.2毫升 = 5000国际单位),于手术前1小时给药,术后每天两次,共7天。对1212例患者(DF组610例,CH组602例)进行了最终评估,这些患者均顺利完成了预防和监测方案。DF组检测到1例PE(0.16%)和38例DVT(6.2%),而接受CH治疗的患者报告有2例PE(0.33%)和40例DVT(6.6%)。DF组术后失血量为578±150毫升(中位数±标准误),CH组为604±123毫升(p值无统计学意义)。69例患者(5.7%)出现伤口血肿:DF组20例(3.2%),CH组49例(8.1%)(卡方检验 = 12.44;p = 0.0005);两组术后红细胞、白细胞、血小板计数和纤维蛋白原均显著下降(p < 0.01)。(摘要截取自250词)